CAR-T therapy developer Senti Biosciences has secured USD 8 million in grant funding from the California Institute for Regenerative Medicines (CIRM) to accelerate the development of Senti's chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy SENTI-202.
The funds will fuel the ongoing Phase I clinical trial of SENTI-202 aimed at treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The initial efficacy data of the trial is to be ready by late 2024 and initial durability data by 2025.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.